An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A Chinese biotech company called Ascletis announced it plans to move a new pill combination into clinical development. The pill pairs two experimental small molecules: ASC48, which activates the GIP receptor, and ASC30, which activates the GLP-1 receptor. Both are being developed as oral (pill) drugs, and the company says this fixed-dose combo is ready for formal testing in people. GLP-1 and GIP are naturally occurring gut hormones that help control appetite and blood sugar. Drugs like semaglutide (brand names Ozempic, Wegovy) mimic GLP-1 and are injected; they tell the brain you're full and slow how fast food leaves the stomach. GIP is a different gut hormone that also affects metabolism and fat handling. Ascletis’s ASC30 is designed to act like GLP-1, and ASC48 is designed to act like GIP, but both are small molecules you can swallow rather than inject. “Small molecule” here means the drug is chemically simple enough to be taken as a pill, unlike larger protein drugs. What Ascletis announced is mainly a development decision, not a finished clinical result. They’ve chosen to move this particular fixed-dose combination into clinical trials, which means testing in humans will start or continue under regulated study conditions. The company calls ASC48 “first-in-class” for an oral GIP receptor activator, implying it’s one of the first of its kind. The news release doesn’t include human efficacy or safety data, so we don’t yet know how well the drugs work together, how big any benefits might be, or how they compare to current injected medicines. The actual effects will only be clearer after completed phase 1 and later trials. This matters because most current GLP-1 drugs that help with diabetes and weight are injections. An effective oral combo that hits both GLP-1 and GIP pathways could offer the convenience of a pill and potentially different or improved metabolic effects. If it works and is safe, it could be of interest to people with type 2 diabetes, obesity, or doctors looking for non-injectable options. It could also change how pharmaceutical companies approach combination therapies in metabolic disease. There are important caveats. This is an early-stage development announcement, not proof of benefit. Pills that act like peptide hormones face challenges: they must survive digestion and reach the right tissues, and small molecules can have different safety profiles than the injected peptide drugs. Side effects common to GLP-1 drugs—nausea, vomiting, diarrhea—could still occur, and new or unexpected risks could appear. Regulatory approval will require multiple successful trials, and many drug candidates never make it that far. Until clinical trial data are published, we don’t know who should or shouldn’t take these drugs, or whether they’ll be approved. Bottom line: Ascletis is moving forward with a promising-sounding oral pill that pairs a GIP activator and a GLP-1 activator, but real answers about safety and effectiveness will only come from upcoming human trials.
Source: PR Newswire